Monitor regulatory approvals (state cannabis authorities) and C21 shareholder vote expected Q3 2026. The stock may trade on deal spread; watch for any competing bids given the $3M termination fee and 12-month tail provision. Historical performance on VREOF calls shows low win rate (25% T+20) and negative alpha (-11.08% vs SPY), but no prior M&A-related reports — this is a new catalyst event. After completion, Vireo gains Nevada scale but must execute integration.
Price Chart
Executive Summary
Vireo Growth Inc. (VREOF) entered into a definitive arrangement agreement to acquire all outstanding common shares of C21 Investments Inc. (CXXIF). C21 shareholders will receive 0.023052 Vireo subordinate voting shares per C21 common share, valuing the consideration at an undisclosed amount. The transaction is expected to expand Vireo's Nevada presence to approximately 15 dispensaries and 158,000 square feet of cultivation/manufacturing space. The deal requires C21 shareholder approval, court approval, and regulatory approvals, with an outside date of May 31, 2027.
Key Financial Metrics
Key Facts
- Vireo Growth Inc. (VREOF) acquiring C21 Investments Inc. (CXXIF) via court-approved plan of arrangement
- Exchange ratio: 0.023052 Vireo subordinate voting shares per C21 common share
- C21's Nevada operations include ~15 dispensaries and 158,000 sq ft cultivation/manufacturing capacity post-acquisition
- Termination fee: $3,000,000 payable by C21 in certain circumstances (superior proposal, adverse recommendation change)
- Expense reimbursement fee: $1,000,000 payable by either party in specified breach-related termination circumstances
- C21 aggregate transaction expenses capped at $2,000,000 as a closing condition for Vireo
- Outside date: May 31, 2027; C21 shareholder meeting expected Q3 2026
Financial Impact
The deal value is not explicitly stated. Vireo issues 0.023052 subordinate voting shares per C21 common share; C21 has 118,678,994 common shares plus 100,000,000 subordinate voting shares outstanding, implying up to ~5.04 million Vireo shares issued at maximum. Vireo's stock price is not provided, so total consideration cannot be calculated. Termination fee is $3,000,000.
Risk Factors
- Regulatory risk: Transaction requires approvals from state cannabis authorities and court approval; U.S. federal illegality of cannabis remains a backdrop risk
- Shareholder approval risk: Requires 66 2/3% majority of C21 shareholders; dissenting shareholders >5% of votes can block condition
- Execution risk: Integration of C21's operations into Vireo's platform may face operational challenges
- Market risk: No financial details (revenue, EBITDA) of C21 are disclosed; synergy estimates are qualitative only
- Dilution risk: Vireo issues up to ~5 million new shares; increase in outstanding shares may pressure stock price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-075721 |
| Document: tm2617497d3_8k.htm | 0001104659-26-075721 |
| Document: tm2617497d3_ex99-1.htm | 0001104659-26-075721 |
| Document: 0001104659-26-075721-index-headers.html | 0001104659-26-075721 |
| Document: 0001104659-26-075721-index.html | 0001104659-26-075721 |
| Document: 0001104659-26-075721.txt | 0001104659-26-075721 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 6w ago | 8-K | $10.97 $12.11 | ▲ +10.39% | ▲ +11.91% | $9.61 (−12.40%) |
Aug 11, 2026 7w ago | 8-K | $10.64 $12.12 | ▲ +13.91% | ▲ +14.97% | $9.61 (−9.68%) |
Aug 5, 2026 8w ago | 8-K | $10.01 $10.84 | ▲ +8.29% | ▲ +7.69% | $9.61 (−4.00%) |
Jul 30, 2026 9w ago | 8-K | $9.44 $10.60 | ▲ +12.29% | ▲ +9.30% | $9.61 (+1.80%) |
Jul 27, 2026 9w ago | 8-K | $9.70 $10.89 | ▲ +12.27% | ▲ +8.97% | $9.61 (−0.93%) |
Jun 18, 2026 15w ago | 8-K | $10.42 $9.80 | ▼ −5.95% | ▼ −5.64% | $9.61 (−7.77%) |
Jun 11, 2026 16w ago | 8-K | $12.46 $10.02 | ▼ −19.58% | ▼ −20.84% | $9.61 (−22.87%) |
Jun 9, 2026 16w ago | 8-K | $12.90 $9.82 | ▼ −23.88% | ▼ −27.77% | $9.61 (−25.50%) |
May 29, 2026 18w ago | 8-K | $13.05 $9.99 | ▼ −23.47% | ▼ −22.17% | $9.61 (−26.34%) |
May 12, 2026 20w ago | 8-K | $12.09 $12.90 | ▼ −6.70% | ▼ −8.43% | $9.61 (+20.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access